Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 11 - 30 tags : Positive save search
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Published: 2021-11-30 (Crawled : 15:00) - biospace.com/
ATRA | $0.7101 -1.18% -1.2% 700K
|
Health Technology
|
| O: -1.52%
H: 0.0%
C: 0.0%
treatment ema europe application therapeutics disease positive iot
DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast Cancer
Published: 2021-11-30 (Crawled : 14:30) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
risk trial positive cancer phase 3 breast cancer initiated her2- her2
Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis
Published: 2021-11-30 (Crawled : 14:00) - biospace.com/
BIOT | $10.15 -0.78% -0.2% 44K
|
|
| O: -0.1%
H: 0.3%
C: 0.3%
fibrosis xin therapeutics phase 1 positive topline cudetaxestat
Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian Cancer
Published: 2021-11-30 (Crawled : 13:00) - globenewswire.com
ZLAB | $15.66 3.57% 3.45% 430K
|
Health Technology
|
| O: -7.63%
H: 0.0%
C: 0.0%
chinese treatment positive therapy women results cancer topline phase 3 ovarian cancer primec
Biomica Reports Positive Results from Pre-Clinical Studies in its Inflammatory Bowel Disease (IBD) Program
Published: 2021-11-30 (Crawled : 13:00) - biospace.com/
EVGN | $0.7 -13.64% 63K
|
Health Technology
|
| O: 2.72%
H: 0.0%
C: 0.0%
disease positive results pre-clinical positive results preclinical
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
Published: 2021-11-30 (Crawled : 12:30) - biospace.com/
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 39.31%
H: 0.0%
C: 0.0%
positive results cancer ovarian cancer trial mirvetuximab topline
First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections
Published: 2021-11-30 (Crawled : 12:00) - globenewswire.com
FWBI | $3.04 -2.56% -2.63% 37K
|
Manufacturing
|
| O: 42.63%
H: 0.0%
C: 0.0%
treatment biopharma test positive gastrointestinal trial covid infections
Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro
Published: 2021-11-30 (Crawled : 07:00) - globenewswire.com
MOLN | $3.88 -3.54% 200
|
Professional, Scientific, and T...
|
| O: 15.09%
H: 7.56%
C: 3.78%
molecular ensovibep xin sars-cov-2 positive in vitro
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.